Search

Displaying results 5791 - 5800 of 10000 in total
  1. Drug

    Cyclo(prolylglycyl)

    go.drugbank.com/drugs/DB04541
    Investigational

    NA-831 (Traneurocin), is under investigation in two clinical trials: NCT03538522 (completed, for mild cognitive impairment and Alzheimer’s disease) and NCT04452565 (unknown status, combination therapy … with Atazanavir and Dexamethasone for COVID-19).

    Synonyms: Cyclo(pro-O-gly)
  2. Drug

    Flurazepam

    go.drugbank.com/drugs/DB00690
    ApprovedIllicit

    A benzodiazepine derivative used mainly as a hypnotic.

  3. Drug

    MK-4830

    go.drugbank.com/drugs/DB17454
    Investigational

    MK-4830 is a monoclonal antibody that targets the myeloid-specific immunoglobulin-like transcript (ILT) 4 receptor.

  4. Drug

    Antipain

    go.drugbank.com/drugs/DB15251
    Experimental

    [A214481] Early studies investigated the potential for antipain to alter DNA damage and chromosomal aberrations in irradiated cells or those treated with chemical mutagens such as _N_-methyl-_N_'-nitro … [A214490] The binding of antipain to OPB has been used in molecular dynamic studies to identify other OPB inhibitors with more favourable pharmacodynamic and pharmacokinetic properties for potential development

  5. Drug

    XC221

    go.drugbank.com/drugs/DB16503
    Investigational

    XC221 was investigated in clinical trials to treat patients with respiratory infections, including influenza, COVID-19, and other acute viral upper respiratory infections.

    Categories: Experimental Unapproved Treatments for COVID-19
  6. Drug

    Surotomycin

    go.drugbank.com/drugs/DB12076
    Investigational

    Surotomycin is non-inferior to vancomycin and offers a promising alternative for the treatment and prevention of C. diff infection. … It is a benzenebutanoic acid derivative patented by Cubist Pharmaceuticals, Inc. as antibacterial agents for the treatment of Gram-positive infections.

  7. Drug

    CTCE-0214

    go.drugbank.com/drugs/DB05934
    Experimental

    CTCE-0214 is a stable peptide agonist of stromal cell-derived factor-1 (SDF-1), a key signaling molecule in the proliferation, homing, engraftment and expansion of hematopoietic stem cells and white blood

  8. Drug

    NCX 1015

    go.drugbank.com/drugs/DB05825
    Experimental

    NCX 1015 is nitric oxide-releasing derivative of prednisolone developed for the treatment of inflammatory bowel disease (IBD) by NicOx SA.

  9. Drug

    SARS-CoV-2 Sclamp

    go.drugbank.com/drugs/DB15849
    Investigational

    The University of Queensland (UQ), in partnership with The Coalition for Epidemic Preparedeness Inovations (CEPI) and CSL has developed a COVID-19 candidate, SARS-CoV-2 Sclamp. … As of July 13, 2020, the candidate is being tested for safety and immunogenicity in Phase 1 clinical trials in Queensland (ACTRN12620000674932).

    Synonyms: UQ COVID-19 Vaccine, UQ-1-SARS-CoV-2-Sclamp
  10. Drug

    OTL-203

    go.drugbank.com/drugs/DB18643
    Investigational

    OTL-203 is an autologous CD34+ enriched cell therapy that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene.

    Synonyms: Autologous CD34+ enriched cell population that contains hematopoietic stem and progenitor cells transduced ex-vivo using a lentiviral vector encoding alpha-L-iduronidase gene